Novel Therapeutics for Metastatic Renal Cell Carcinoma

被引：18
作者：
Hutson, Thomas E. [2 ]
Figlin, Robert A. [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Div Med Oncol & Expt Therapeut, Duarte, CA 91010 USA
[2] Baylor Sammons Canc Ctr, Genitourinary Oncol Program, Dallas, TX USA
来源：
CANCER | 2009年 / 115卷 / 10期
关键词：
renal cell carcinoma; angiogenesis inhibitors; targeted therapy; sunitinib; sorafenib; temsirolimus; bevacizumab; everolimus; INTERFERON-ALPHA; DOUBLE-BLIND; PATIENTS PTS; CANCER; EXPRESSION; RCC; ANGIOPOIETIN-2; TIE2;
D O I：
10.1002/cncr.24235
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically during the past few years. Sunitinib malate, sorafenib tosylate, bevacizumab with interferon alpha, temsirolimus, and everolimus have improved clinical outcomes in randomized phase 3 trials by inhibiting the vascular endothelial growth factor and related pathways. Combinations and sequences of these agents are being evaluated. Other novel agents are in clinical development, some of which target novel pathways not yet exploited as therapy for RCC. Recently reported and ongoing clinical trials will help further define the role of these agents as therapy for metastatic RCC. Cancer 2009;115(10 suppl):2361-7. (C) 2009 American Cancer Society.
引用
收藏
页码：2361 / 2367
页数：7
相关论文
共 29 条
  • [1] *AMG 386 INV, AMG 386 INV BROCH
  • [2] [Anonymous], J CLIN ONCOL S
  • [3] [Anonymous], J CLIN ONCOL
  • [4] Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia
    Currie, MJ
    Gunningham, SP
    Turner, K
    Han, C
    Scott, PAE
    Robinson, BA
    Chong, W
    Harris, AL
    Fox, SB
    [J]. JOURNAL OF PATHOLOGY, 2002, 198 (04) : 502 - 510
  • [5] Eder JP, 2007, J CLIN ONCOL, V25
  • [6] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Escudier, Bernard
    Pluzanska, Anna
    Koralewski, Piotr
    Ravaud, Alain
    Bracarda, Sergio
    Szczylik, Cezary
    Chevreau, Christine
    Filipek, Marek
    Melichar, Bohuslav
    Bajetta, Emilio
    Gorbunova, Vera
    Bay, Jacques-Olivier
    Bodrogi, Istvan
    Jagiello-Gruszfeld, Agnieszka
    Moore, Nicola
    [J]. LANCET, 2007, 370 (9605) : 2103 - 2111
  • [7] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 125 - 134
  • [8] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1
    Gale, NW
    Thurston, G
    Hackett, SF
    Renard, R
    Wang, Q
    McClain, J
    Martin, C
    Witte, C
    Witte, MH
    Jackson, D
    Suri, C
    Campochiaro, PA
    Wiegand, SJ
    Yancopoulos, GD
    [J]. DEVELOPMENTAL CELL, 2002, 3 (03) : 411 - 423
  • [10] Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
    Griffiths, RW
    Gilham, DE
    Dangoor, A
    Ramani, V
    Clarke, NW
    Stern, PL
    Hawkins, RE
    [J]. BRITISH JOURNAL OF CANCER, 2005, 93 (06) : 670 - 677
123